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Objective: We and others have observed significant hyperinflation and airflow
obstruction after the surgical repair of pulmonary atresia and ventricular septal
defect. This study sought to objectively characterize this problem and determine the
prevalence of airway hyperresponsiveness in these patients.
Methods: We performed a prospective study of children and young adults with pul-
monary atresia and ventricular septal defect between June 1996 and December
1998. The participants were stratified into 2 distinct molecular genotypes on the
basis of chromosome 22q11.2 microdeletion. A clinical diagnosis of asthma and an
objective assessment of airway hyperresponsiveness were determined by means of
an asthma inventory scale and methacholine challenge testing, respectively. Thirty-
three patients were enrolled. Thirteen had velocardiofacial syndrome, each with
chromosome 22q11.2 microdeletion.
Results: None of the nonsyndromic patients had evidence for haploinsufficiency.
Overall, 66.7% (22/33) met criteria for a clinical diagnosis of airway hyperrespon-
siveness: 62% (8/13) from the microdeletion genotype and 70% (14/20) from the
nonsyndromic group.
Conclusions: We have identified an extremely strong association between pul-
monary atresia and ventricular septal defect and persistent airway hyperresponsive-
ness. Haploinsufficiency at chromosome 22q11.2 did not contribute to this predilec-
tion for airway hyperresponsiveness. These results provide a basis to anticipate
persistent respiratory difficulties after operations in patients with pulmonary atresia
and ventricular septal defect. Moreover, this at-risk patient population may yield
unique insights into fundamental mechanisms involved in the pathogenesis of air-
way hyperresponsiveness.
The relationship between congenital heart disease and pulmonaryfunction is not fully understood. Although clinicians are often facedwith patients in whom both congenital heart disease and airway dis-ease coexist, the prevalence of asthma or airway hyperresponsive-ness (AHR) in patients with congenital heart disease is unknown.However, this unique population could have several fundamental
physiologic mechanisms operating whereby airflow limitation could occur, leading
to a higher propensity for development of AHR than the roughly 7% point preva-
lence for clinical asthma found in the general population.1
In our experience significant pulmonary complications, including dyspnea,
hypoxia, pulmonary hyperinflation (evident by chest imaging), atelectasis, and
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bronchodilator-responsive wheezing, appear to occur at a
greater frequency in children immediately after surgical
repair of pulmonary atresia and ventricular septal defect
(PA-VSD) than for other congenital cardiac abnormalities.
These postoperative pulmonary complications have con-
tributed to early mortality.2,3 It appeared as though patients
with PA-VSD associated with velocardiofacial syndrome
(VCFS) were particularly prone to these pulmonary compli-
cations. In a retrospective study, Jedele and colleagues3
demonstrated that 7 of the 15 patients with VCFS and PA-
VSD had experienced significant “bronchospasm” after car-
diac operations. Others4 have reported significant pul-
monary complications after PA-VSD, including 1-stage
complete unifocalization and repair of PA-VSD. Moreover,
in children after surgical correction of PA-VSD, the clinical
manifestations of asthma (wheezing and severe hyperinfla-
tion) are severe, at times treated with continuous β2-agonist
aerosols or volatile anesthetic agents.5
However, it remains unclear whether these pulmonary
complications are merely an immediate comorbid event in
the surgical repair of such a complex congenital heart lesion
or whether children with PA-VSD have persistent AHR. We
sought to explore the relationship among PA-VSD, VCFS,
and AHR in this prospective study. We hypothesized that the
postoperative respiratory complications occurred in PA-
VSD, possibly because the cardiac lesion provided the sub-
strate for AHR or the altered bronchopulmonary circulation
after the surgical repair elicited AHR. If the development of
AHR was a consequence of hemodynamic alterations or
abnormal bronchial development associated with PA-VSD,
then the frequency of AHR should be similar between
patients with PA-VSD with and without VCFS. On the other
hand, if AHR was more common in patients with VCFS
than in patients without VCFS, then one could consider a
role for haploinsufficiency at chromosome 22q11.2 in the
pathogenesis of AHR. Clarification of these issues may
offer important clinical insight into the management of
patients with PA-VSD and may illuminate a fundamental
interrelationship between complex congenital heart disease
and AHR.
Methods
Study Design
This prospective study of children, adolescents, and young adults
at least 5 years of age with PA-VSD was conducted between June
1996 and December 1998 by the pediatric cardiologists at Mayo
Clinic (Rochester, Minn). This minimum age was selected because
children under 5 years of age are generally unable to perform reli-
able pulmonary function testing. The study was reviewed and
approved by the Institutional Review Board of the Mayo
Foundation. Informed consent was obtained from each participant
and his or her legal guardian. Exclusion criteria included a history
of tobacco use or coexistence of major pulmonary diseases, such
as bullous emphysema, pulmonary fibrosis, α1-antitrypsin defi-
ciency, cystic fibrosis, or bronchiectasis. No patient met these
exclusion criteria. In addition, the patient was ineligible unless at
least 6 months had elapsed since the most recent chest operation to
minimize the confounding influence of a recent thoracotomy or
sternotomy on pulmonary function testing.
Study Maneuvers
Each participant was evaluated clinically for VCFS and AHR. This
permitted the initial stratification of the participants into 2 clinical
study groups: nonsyndromic and VCFS. Next, a blood sample was
obtained for fluorescent in situ hybridization (FISH) analysis of
chromosome 22q11.2 microdeletion, enabling classification of 2
distinct molecular genotypes of PA-VSD: normal and haploinsuf-
ficient at chromosome 22q11.2. Finally, the majority (18/20) of the
nonsyndromic group of PA-VSD completed pulmonary function
testing with methacholine challenge testing to assess objectively
the presence of AHR. At the outset, methacholine challenge testing
was intended for both genotypic subsets of PA-VSD. However, we
were unable to obtain acceptable and reproducible results in most
of those with VCFS (5/13 tested) because of their intellectual
impairment.
Clinical Diagnosis of VCFS
The patient was required to manifest 2 cardinal features in addi-
tion to their cardiac malformation to be considered syndromic
with VCFS: (1) velopharyngeal incompetence, as evidenced by
either a history of cleft palate, pharyngeal hypotonia, bifid uvula,
or hypernasal speech, and (2) a stereotypical facies characterized
by a long narrow face with an elongated philtrum, a long promi-
nent nose with a squared nasal bridge, a narrow alar base, malar
hypoplasia, small palpebral fissures, and thickening of the ear’s
superior helices. Crifasi and coworkers6 demonstrated previously
that if the patient possessed these 3 principal features of VCFS,
there was 100% detection of the 22q11.2 microdeletion with the
FISH probe.
FISH With DNA Probe TUPLE1 for Chromosome
22q11.2 Microdeletion
The procedure for FISH has been described previously for detec-
tion of the chromosome 22q11.2 microdeletion and is modified
here by using the diagnostic DNA probe TUPLE1 and the control
probe D22S39.6
Clinical Diagnosis of AHR
Each participant had an asthma inventory scorecard completed by
the pediatric cardiologist evaluating the patient in the clinic. The
asthma inventory scale for the clinical diagnosis of AHR was
adapted from an asthma epidemiology study for Olmsted County
by Yunginger and associates.1 The asthma inventory scale com-
prised 3 major criteria and 10 minor criteria. The major criteria
included a previous physician-made diagnosis of asthma; a history
of cough, dyspnea, and/or wheezing; and substantial variability in
symptoms from time to time or periods of weeks or more during
which the patient is symptom free.
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The minor criteria included sleep disturbance caused by noc-
turnal cough and wheeze; nasal polyps; blood eosinophilia of
greater than 300/µL; positive wheal and flare skin test responses;
elevated serum immunoglobulin E levels; history of hay fever,
infantile eczema, or atopic dermatitis; family history of atopy as
manifested by asthma, hay fever, allergic rhinitis, or eczema;
cough, dyspnea, and wheezing with regular exposure to a specific
antigen; favorable clinical response to bronchodilator; and positive
methacholine challenge test response showing greater than 20%
fall in forced expiratory volume in 1 second (FEV1; see below).
A study candidate was considered to have clinical evidence for
AHR if he or she satisfied any 2 of the 3 major criteria or possessed
1 major criterion along with at least 2 minor criteria.
Pulmonary Function Testing, Including Methacholine
Challenge Testing
After baseline spirometry, an inhalational methacholine challenge
protocol to assess AHR was used.7 A participant with a baseline
FEV1/forced vital capacity (FVC) ratio of 70% or greater was
challenged initially with a single breath of 1 mg/mL methacholine.
This initial dose is consistent with the starting dose used in the
Lung Health Study involving smokers with known airflow limita-
tion.8 After this single breath of methacholine, the FEV1 was mea-
sured within 3 minutes. If the FEV1 did not decrease by 20%, then
1 inhalation of 5 mg/mL methacholine was administered. Again, in
the absence of a 20% decrement in FEV1, the administered dose
was increased to 1 breath of 25 mg/mL methacholine and followed
by 4 additional breaths of 25 mg/mL methacholine. If the initial
FEV1/FVC ratio was less than 70%, the methacholine challenge
was initiated at 0.2 mg/mL methacholine.
AHR after methacholine challenge testing was analyzed as a
continuous variable by an estimate of the overall slope of the dose-
response relationship. Although logarithmic transformations have
been used to compress skewing of the distribution in the dose-
response slope, no assumptions were made about the distribution
of dose-response slope in this study. Simply, the dose-response
slope was defined as the percentage decline in FEV1 after the final
dose of methacholine compared with the postdiluent value divided
by the final breath units of methacholine inhaled. Subjects are gen-
erally considered to have objective evidence for AHR (ie, a posi-
tive methacholine challenge) if there is at least a 20% decline in
FEV1 after the inhalation of 5 breaths of 25 mg/mL methacholine.7
By using this AHR index equation (percent change in FEV1/dose
× number of breaths), this positive challenge would equal 0.16
(20% divided by 125, where 125 is the breath units derived by mul-
tiplying the dose [25 mg/mL] times the breaths, 5). This equation
was normalized by dividing all participants’ AHR indexes by 0.16
(a positive challenge), such that an AHR index of 1 or greater
denotes a positive methacholine challenge. Translating this AHR
index to previous reports by Tashkin and coworkers,9 an AHR index
of 1 indicates that a participant demonstrates significant AHR, and
an AHR index of 25 or greater indicates pronounced AHR.
Statistical Analysis
All data are expressed as raw data and mean values. Associations
between clinical variables and the presence of clinically defined
asthma were assessed on the basis of the Fisher exact test for
dichotomous variables and the Wilcoxon rank sum test for ordinal
or continuously scaled variables. All reported P values are 2-sided.
Results
Demographics of Study Population
Table 1 summarizes the patient characteristics from this 21⁄2-
year prospective enrollment. There were 33 patients with
PA-VSD enrolled; 20 patients were determined to be non-
syndromic, and 13 patients had phenotypic criteria clinical-
ly suggestive of VCFS. This stratification based on pheno-
type was corroborated by molecular genotyping for the
chromosome 22q11.2 microdeletion. None of the 20 non-
syndromic patients were haploinsufficient at chromosome
22q11.2, whereas each of the 13 individuals with VCFS had
the microdeletion. There were 19 men and 14 women, with
the majority (28/33) being white. The average age was 12.6
years (range, 6-23 years) in the nonsyndromic group and 10
years (range, 5-22 years) in the subset with VCFS.
AHR in Patients With PA-VSD
On the basis of the asthma inventory scale, 22 (66.7%) of 33
patients were found to have clinical evidence of AHR. There
was not a significant difference in the frequency of AHR in
the 2 subsets (14/20 [70%] nonsyndromic versus 8/13
[62%] with the chromosome 22q11.2 microdeletion; Figure
1). The clinical diagnosis of AHR was objectively measured
by quantitating the response to methacholine challenge test-
ing during pulmonary function testing. Ninety percent
(18/20) of the nonsyndromic cohort completed pulmonary
function testing. Sixteen of these 18 individuals had a posi-
TABLE 1. Study demographics
Nonsyndromic Patients 
patients with VCFS
No. enrolled 20 13
Male/female 11/9 8/5
No. of white subjects 17 11
Average age, y (range) 12.6 (6-23) 10 (5-22)
Clinical AHR 14 (70%) 8 (62%)
Positive methacholine challenge response 16/18 (89%) 3/5 (60%)
Surgical summary
No. of thoracotomies (range) 1.7 (0-4) 1.6 (0-4)
No. of sternotomies (range) 1.6 (0-5) 1.8 (1-4)
Status of repair
Complete 7 6
Incomplete 13 7
Interval between PFT and most recent 28 (11-60) 49.6 (36-71)
operation, mo (range)
Left ventricular ejection fraction, % (range) 58 (25-66) 60 (54-65)
PFT, Pulmonary function testing.
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tive methacholine challenge test response indicative of sig-
nificant AHR, including 3 who had no attributable respira-
tory symptoms (Figures 2 and 3). The cumulative results of
the baseline spirometry testing (Figure 4) and methacholine
challenge testing (Figure 5) are shown for the cohort of
patients with PA-VSD who were normal at chromosome
22q11.2 (ie, nonsyndromic). Early in the course of this
prospective enrollment, we discovered that most patients
with VCFS were unable to complete the pulmonary function
testing because of their learning disability. Only 5 of the 13
individuals with VCFS were able to complete spirometry
and methacholine challenge. Three of the 5 had a positive
challenge result.
In the nonsyndromic cohort, 13 of the 14 patients with
clinical AHR had a methacholine challenge test per-
formed, and all 13 had a positive methacholine challenge
result (Figure 2). The typical baseline spirometry test
revealed a pattern of proportionately decreased FEV1 and
Surgery for Congenital Heart Disease Ackerman et al
Figure 2. Summary of methacholine challenge testing in nonsyndromic PA-VSD. For the 20 nonsyndromic patients
enrolled in this study, 2 did not complete methacholine challenge testing (open bars), 2 had a negative metha-
choline challenge test response (hatched bars), and 16 had a positive methacholine challenge test response
(filled bars).
Figure 1. Clinical diagnosis of asthma in patients with PA-VSD on the basis of the chromosome 22q11.2 microdele-
tion genotype. Open bars indicate that the patient had no clinical evidence for AHR on the basis of the asthma
inventory scale, and filled bars denote patients with clinical AHR.
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Figure 3. Example of reversible airflow obstruction and methacholine challenge test in a nonsyndromic individual
with asthma. This particular study was performed on a 15-year-old boy exhibiting proportionate reduction in FEV1
(64%) and FVC (59%), with a preserved FEV1/FVC ratio of 93%. After administration of 3 breaths of 25 mg/mL metha-
choline, the FEV1 decreased by 43% (AHR index, 3.6). The solid line indicates the predicted flow volume curve. The
patient’s prechallenge curve is indicated by the long-dashed line, the postmethacholine challenge is indicated by
the dashed-and-dotted line, and the patient’s curve after albuterol inhalation is shown with the short-dashed line.
Figure 4. Baseline spirometry in nonsyndromic PA-VSD. Baseline FVC, FEV1, and the FEV1/FVC ratio are summa-
rized for the 18 of 20 nonsyndromic patients who completed pulmonary function testing. Triangles represent the
data points for those with a negative methacholine challenge test response (n = 2), diamonds represent data from
clinically asymptomatic patients with a positive methacholine challenge test response (n = 3), and circles repre-
sent data for patients with a positive methacholine challenge test response who also had a clinical impression
of AHR (n = 13). Numbered open squares indicate the mean value.
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FVC with a normal FEV1/FVC ratio (Figure 4). The FVC
was reduced on average to 69% of predicted value (Table
1). In contrast to the scooped flow-volume loop of an
asthmatic subject in which the FEV1/FVC ratio is
reduced, the FEV1/FVC ratio averaged 86% of predicted
value, with many participants having no reduction at all.
Of the 5 nonsyndromic patients with no clinical evidence
suggestive of asthma, 3 individuals had a positive metha-
choline challenge test response (Figure 2).
Figure 5 summarizes the results of methacholine chal-
lenge testing and reversibility after bronchodilator therapy.
A methacholine challenge test response is considered sig-
nificant or positive when there is at least a 20% reduction in
FEV1 after the administration of 5 breaths of 25 mg/mL
methacholine. This threshold was assigned an AHR index of
1, permitting a continuous variable assessment of AHR. All
of the individuals with clinical AHR who were tested from
the nonsyndromic cohort (n = 13) had objective confirma-
tion for the presence of AHR with a positive methacholine
challenge test response. The average AHR index was 9.9
(range, 1.25-46.25). The bronchoconstriction elicited by
methacholine was completely reversed (95%) after inhala-
tion of albuterol.
Because the participants’ chromosome 22q11.2 geno-
type did not influence the prevalence of AHR in these indi-
viduals with PA-VSD, we examined several variables that
might distinguish those individuals with AHR from those
without AHR. Table 2 summarizes the results of several
potential confounding variables for the 26 patients with
either clinical AHR, positive methacholine challenge
results, or both, and the 7 patients with no suggestion of
clinical AHR. A similar analysis was performed separating
the 2 subsets on the basis of the asthma inventory scale
alone (ie, 22 positive for AHR and 11 asymptomatic) in the
event that the 4 positive methacholine challenge results in
clinically asymptomatic individuals represented false-posi-
tive challenges. In both analyses the extent of the patient’s
surgical history did not affect the likelihood of having a
positive methacholine challenge response. Only 1 patient in
this series had no prior cardiovascular operations, and
therefore no conclusion can be drawn as to the presence of
preoperative de novo AHR.
No statistically significant differences in surgical status
(complete repair vs staged), number of thoracotomies or
sternotomies, total number of cardiac operations, or interval
elapsed between the most recent operation and the pul-
monary function test were identified (Table 2). The proba-
bility of AHR did not appear to be influenced by either the
Surgery for Congenital Heart Disease Ackerman et al
Figure 5. AHR to methacholine and reversibility with albuterol in nonsyndromic PA-VSD. Summary of metha-
choline challenge testing in the nonsyndromic patients tested (18/20) is shown. Triangles represent the data points
for those with a negative methacholine challenge test responses (n = 2), diamonds represent data from clinically
asymptomatic patients with positive methacholine challenge test responses (n = 3), and circles represent data for
those with positive methacholine challenge test responses who also had a clinical impression of AHR (n = 13).
Numbers in open squares indicate the mean value. An AHR index of 1 or greater indicates significant AHR 
(see text).
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patient’s original cardiopulmonary anatomy in terms of
hypoplastic central pulmonary arteries and confluent versus
nonconfluent pulmonary arteries and the nature and extent
of systemic bronchial collateral pulmonary blood flow or
the duration of exposure to excessive pulmonary blood flow
through a persistent ductus, a surgical aortopulmonary con-
nection, or a large aortopulmonary collateral (data not
shown). The mean M-mode–derived ejection fraction for
left ventricular function was similar between those with and
without AHR (58.3% vs 61.9%). Diastolic dysfunction and
elevated left ventricular end-diastolic pressures were not
found, except in 1 individual (17 year-old male patient,
unoperated, no clinical AHR, positive methacholine chal-
lenge result) with a left ventricular ejection fraction of 25%.
Finally, we were unable to implicate secondary exposure to
household tobacco smoke or a history of respiratory syncy-
tial virus infection or bronchiolitis in distinguishing those
with asthma (data not shown).
Discussion
The main finding of this study is the identification of a
strong association (66.7%) between PA-VSD and AHR.
Irrespective of genotype (at chromosome 22q11.2), two
thirds of this PA-VSD cohort satisfied requirements for the
clinical diagnosis of asthma. The diagnosis of asthma8
is based on pathobiology (airway inflammation) and its
functional effect (airflow limitation). Because we did not
determine the presence of airway inflammation in these
patients, we accordingly limit their characterization to the
less restrictive term AHR. Indeed, we found that metha-
choline challenge testing objectively demonstrated signifi-
cant and reversible AHR in all patients with a positive asth-
ma inventory scorecard.
In this study pulmonary function testing revealed a nearly
uniform reduction in both FVC (mean, 69%) and FEV1
(mean, 62%). These results are intriguing but also highlight a
flaw in our study design. Because proportionate reductions in
FEV1 and FVC can occur either in primarily obstructive or
restrictive lung diseases, future studies are required to deter-
mine whether the decrease in FVC is due to hyperinflation or
restriction. However, Furrer and associates10 compared spiro-
metric data in 15 consecutive patients who underwent thora-
cotomy and found that the FVC was decreased slightly during
the early postoperative period but approached predicted values
after 4 months. Because our study required 6 months since the
last sternotomy or thoracotomy for enrollment and because
chest imaging noted significant hyperinflation in the majority
of patients (data not shown), we favor the possibility that the
reduction in FVC was due to hyperinflation.
Before this systematic prospective study, only a few
descriptive reports11-14 have suggested that asthma or AHR
might be more common in children with specific congenital
heart defects. Tsubata and coworkers11 found that 6 of 10 chil-
dren with congestive heart failure caused by congenital heart
disease had AHR elicited by histamine challenge. However,
the hemodynamic abnormality in their patients, namely ele-
vated pulmonary venous pressure, is not typical in patients
with PA-VSD. In fact, only 1 of our 33 patients had evidence
for elevated left ventricular end-diastolic pressure. Matsuoka
and colleagues13,14 suggested an association between pul-
monary vascular congestion and the development of atopic
asthma. These investigators found that a clinical diagnosis of
asthma was more common in patients with congenital heart
disease and high pulmonary blood flow (19% [39/201]) com-
pared with those with normal (5% [6/117]) or reduced (1%
[1/130]) pulmonary blood flow. Although pulmonary hyper-
tension or excessive pulmonary blood flow is not typically
seen in PA-VSD, these patients may indeed have heteroge-
neous local pulmonary blood flow patterns throughout the
lungs, with some lung segments being underperfused and
other segments being relatively overperfused.
Why is there a strong association between PA-VSD and
AHR? Haploinsufficiency at chromosome 22q11.2 did not
contribute to this predilection for AHR. Thus it is unlikely
that a gene responsible for bronchial smooth muscle tone
resides in the region of the microdeletion. Conceivably, a
small deletion, undetected by the TUPLE1 probe, may be
TABLE 2. Variables in patients with PA-VSD with and with-
out AHR
Positive AHR Negative AHR 
Variable (n = 26) (n = 7) P value
Complete repair 9 (34.6%) 4 (57.1%) .393
No. of thoracotomies
Mean 1.7 1.6 .539
Median 2.0 1.0
Range 0-4 0-4
No. of sternotomies
Mean 1.5 2.1 .108
Median 1.0 2.0
Range 0-5 1-4
Total No. of operations
Mean 3.2 3.7 .499
Median 3.0 4.0
Range 0-6 2-6
Interval between PFT and most 
recent operation (mo)
Mean 31.1 33.8 .966
Median 31.5 30
Range 11-69 4-71
Left ventricular ejection fraction (%)
Mean 58.3 61.9 .522
Median 60 63
Range 25-68 53-65
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present in both patient subsets and could be responsible for
this conotruncal malformation and AHR.
Moreover, it is doubtful that the distinct pulmonary cir-
culation present in chromosome 22q11.2 haploinsufficient
individuals with PA-VSD accounts for the AHR. Chessa and
associates15 reviewed the morphologic characteristics of the
pulmonary vascular bed in 40 consecutive infants with PA-
VSD with and without the 22q deletion. They found that
major aortopulmonary collateral arteries with complex loop
structure, anastomoses with the small confluent central pul-
monary artery outside the lung, and absent ductus arteriosus
were associated with PA-VSD and 22q deletion and less
common in those without 22q deletion. These morphologic
differences in the pulmonary circulation may reflect differ-
ences in embryogenesis critical to cardiopulmonary devel-
opment in patients with and without the 22q deletion.
Nonetheless, it does not appear that these morphologic dis-
tinctions account for the pathogenesis of AHR because both
patient subsets in our study were equally prone to the devel-
opment of AHR.
The strong association between PA-VSD and asthma
could be the result of several clinical factors, including sur-
gical history, ventricular function, passive exposure to
tobacco smoke, or past respiratory syncytial virus or bron-
chiolitis infection. However, none of these variables was
associated with AHR. Alternative cardiac or pulmonary
anatomic functional mechanisms must be considered in PA-
VSD. Normally, bronchopulmonary anastomotic blood flow
is influenced by the relative pulmonary venous, alveolar,
and bronchial artery pressures and can influence small air-
way aperture.16 Clearly, patients with PA-VSD have an
abnormal bronchopulmonary circulation based, at least in
part, on an incomplete native pulmonary circulation and
enhanced bronchial circulation. Moreover, blood flow
through the native pulmonary circulation may occur through
central or peripheral pulmonary vascular stenoses, leading
to heterogeneous patterns of lung perfusion. In addition, the
relative contribution of pulmonary blood flow derived from
the systemic bronchial circulation varies, and operations
may further perturb bronchial blood flow as a consequence
of interruption of established bronchial collaterals, leading
to the reestablishment of segmental blood flow through pre-
viously underperfused pulmonary arteries. This unusual
bronchopulmonary anastomotic blood flow may alter
bronchial tone and aperture.
Finally, there may be other intrinsic parenchymal lung
abnormalities in PA-VSD. For example, Rabinovitch and
coworkers17 found a significant reduction in the total num-
ber of the alveoli, with preserved lung volume as a result of
increased mean alveolar size. This suggests that morpho-
genesis of the pulmonary circulation and lung development
may be fundamentally interrelated. Insofar as lung elastance
may be reduced in the setting of increased mean alveolar
size, the measured load against which airway smooth mus-
cle contracts18 may be reduced in PA-VSD, leading to an
increase in AHR.
In summary, we have identified an extremely strong asso-
ciation (66.7%) between PA-VSD and AHR independent of
the chromosome 22q11.2 genotype. Although we have not
identified the physiologic underpinning of AHR in these
patients, these results provide a strong rationale to anticipate
and aggressively manage persistent AHR in both the preop-
erative and postoperative settings. Moreover, this at-risk
patient population may yield unique insights into the funda-
mental mechanisms involved in the pathogenesis of AHR.
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